A W Armstrong
Overview
Explore the profile of A W Armstrong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
744
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gustafson A, Gelfand J, Davies J, Lieberman A, Mason J, Armstrong A, et al.
J Psoriasis Psoriatic Arthritis
. 2023 Dec;
7(4):174-186.
PMID: 38148879
Background: Psoriasis is an immune-mediated disease associated with excess risk for cardiovascular disease (CVD). Guidelines recognize psoriasis as a CVD risk enhancer; however, psoriasis patients often do not have CVD...
2.
Balak D, Perez-Chada L, Guo L, Mita C, Armstrong A, Bell S, et al.
J Eur Acad Dermatol Venereol
. 2022 Aug;
36(12):2291-2300.
PMID: 35924437
Psoriasis studies increasingly employ outcomes that indicate complete disease resolution, yet remission and cure are poorly defined for psoriasis. We conducted a systematic literature review to identify definitions of psoriasis...
3.
Reich K, Gordon K, Strober B, Armstrong A, Miller M, Shen Y, et al.
Br J Dermatol
. 2021 Jun;
185(6):1146-1159.
PMID: 34105767
Background: Psoriasis is a chronic disease requiring long-term therapy. Objectives: Physician- and patient-reported outcomes were evaluated through week 252 in VOYAGE 1 and VOYAGE 2. Methods: In total, 1829 patients...
4.
Kassardjian A, Chat V, Archuleta L, Hekmatjah J, Sierro T, Read C, et al.
Br J Dermatol
. 2020 Dec;
184(5):971-973.
PMID: 33332578
No abstract available.
5.
Li N, Teeple A, Muser E, You Y, Song M, Armstrong A
J Dermatolog Treat
. 2020 Apr;
33(1):278-283.
PMID: 32233940
Background: Work productivity loss (WPL) is a major contributor to the indirect costs of psoriasis. Newer biologic therapies are effective at reducing disease symptoms and improving quality of life, but...
6.
Armstrong A, Blauvelt A, Crowley J, Gordon K, Krueger G, Krueger J, et al.
Br J Dermatol
. 2019 Nov;
182(6):1484-1487.
PMID: 31705649
No abstract available.
7.
Deng P, Wang C, Armstrong A
Br J Dermatol
. 2019 Aug;
182(2):490-491.
PMID: 31407315
No abstract available.
8.
Jemec G, Okun M, Forman S, Gulliver W, Prens E, Mrowietz U, et al.
Br J Dermatol
. 2019 Mar;
181(5):967-975.
PMID: 30916379
Background: Weekly adalimumab (Humira ) is approved for the treatment of hidradenitis suppurativa (HS) based on the 12-week placebo-controlled periods of the two phase III PIONEER trials. Objectives: Using PIONEER...
9.
Reich K, Papp K, Armstrong A, Wasfi Y, Li S, Shen Y, et al.
Br J Dermatol
. 2018 Nov;
180(5):1039-1049.
PMID: 30485400
Background: Long-term evaluation is required to confirm the safety profile of newer biologic agents. Objectives: To report on pooled safety data from the ongoing VOYAGE 1 (NCT02207231) and VOYAGE 2...
10.
Langley R, Armstrong A, Lebwohl M, Blauvelt A, Hsu S, Tyring S, et al.
Br J Dermatol
. 2018 Oct;
180(2):306-314.
PMID: 30328108
Background: Brodalumab, a fully human anti-interleukin-17 receptor A monoclonal antibody, has demonstrated superior efficacy and safety over ustekinumab as induction therapy for moderate-to-severe psoriasis. Objectives: To evaluate the efficacy and...